CoChat

Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT

Open access

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS: Recently diagnosed, drug-naïve patients with type 2 diabetes (4,360 total) were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic testing using an OGTT. RESULTS: Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide. Persistent improvements were seen in those who completed 4 years of monotherapy and marked deterioration of β-cell function in those who failed to maintain adequate glucose control with initial monotherapy. CONCLUSIONS: The favorable combined changes in β-cell function and insulin sensitivity over time with rosiglitazone appear to be responsible for its superior glycemic durability over metformin and glyburide as initial monotherapy in type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db10-1392

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Baseline adjusted geometric mean levels in the full cohort within each treatment group over 4 years of follow-up for OGTT-derived dynamic measure of the early insulin response (A; insulinogenic index; insulin30 − insulin0/glucose30 − glucose0) and insulin sensitivity (B; 1/fasting insulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (± SE asymmetric limits).
FIG. 1. Baseline adjusted geometric mean levels in the full cohort within each treatment group over 4 years of follow-up for OGTT-derived dynamic measure of the early insulin response (A; insulinogenic index; insulin30 − insulin0/glucose30 − glucose0) and insulin sensitivity (B; 1/fasting insulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (± SE asymmetric limits).CC BY-NC-ND · PubMed Central
FIG. 2. Baseline adjusted geometric mean levels in the 4-year completer cohort within each treatment group over 4 years of follow-up for OGTT-derived dynamic measure of the early insulin response (A; insulinogenic index; insulin30 − insulin0/glucose30 − glucose0) and insulin sensitivity (B; 1/fasting insulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (± SE asymmetric limits).
FIG. 2. Baseline adjusted geometric mean levels in the 4-year completer cohort within each treatment group over 4 years of follow-up for OGTT-derived dynamic measure of the early insulin response (A; insulinogenic index; insulin30 − insulin0/glucose30 − glucose0) and insulin sensitivity (B; 1/fasting insulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (± SE asymmetric limits).CC BY-NC-ND · PubMed Central
FIG. 3. Baseline adjusted geometric mean levels in the 4-year monotherapy failure cohort within each treatment group over 4 years of follow-up for OGTT-derived dynamic measure of the early insulin response (A; insulinogenic index; insulin30 − insulin0/glucose30 − glucose0) and insulin sensitivity (B; 1/fasting insulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (± SE asymmetric limits).
FIG. 3. Baseline adjusted geometric mean levels in the 4-year monotherapy failure cohort within each treatment group over 4 years of follow-up for OGTT-derived dynamic measure of the early insulin response (A; insulinogenic index; insulin30 − insulin0/glucose30 − glucose0) and insulin sensitivity (B; 1/fasting insulin). Each was analyzed using the log-transformed values, and the results presented are geometric means (± SE asymmetric limits).CC BY-NC-ND · PubMed Central
FIG. 4. Vector plot of the joint changes in the baseline adjusted geometric mean levels (± SE asymmetric limits) of the OGTT-derived dynamic measure of the early insulin response (insulinogenic index; insulin30 − insulin0/glucose30 − glucose0) and insulin sensitivity (1/fasting insulin) over time within each treatment group over 4 years of follow-up in the full (A), 4-year completer (B), and 4-year monotherapy failure (C) cohorts. The changes are plotted relative to the regression line of the baseline levels (the concave line). The dots represent the baseline measurements, that after 6 months and each annual assessment thereafter, and the arrow the directional change with time. The 95% confidence bands for the baseline relationship are illustrated. The SE limits for the individual time points have been omitted for clarity.
FIG. 4. Vector plot of the joint changes in the baseline adjusted geometric mean levels (± SE asymmetric limits) of the OGTT-derived dynamic measure of the early insulin response (insulinogenic index; insulin30 − insulin0/glucose30 − glucose0) and insulin sensitivity (1/fasting insulin) over time within each treatment group over 4 years of follow-up in the full (A), 4-year completer (B), and 4-year monotherapy failure (C) cohorts. The changes are plotted relative to the regression line of the baseline levels (the concave line). The dots represent the baseline measurements, that after 6 months and each annual assessment thereafter, and the arrow the directional change with time. The 95% confidence bands for the baseline relationship are illustrated. The SE limits for the individual time points have been omitted for clarity.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 1

  1. Faulenbach, 2008, Prevalence of negative insulinogenic index by glucose tolerance in three different cohorts, Diabetes, 57, A669

Cited by

See all 249

Metadata

Authors
Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., & and the ADOPT Study Group
Affiliations
  • University of Washington (US)
  • George Washington University (US)
  • Mount Sinai Hospital (CA)
  • San Antonio Texas
  • GlaxoSmithKline (United States) (US)
  • University of Michigan (US)
  • King's College London (GB)
  • University of Oxford (GB)
Corresponding author
Kahn, Steven E.
Venue
Diabetes
Published
2011-04-23
Volume
60
Issue
5
Pages
1552-1560
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2111473023
Cited by
249
References
25
Citations by year
2026: 6 · 2025: 11 · 2024: 21 · 2023: 20 · 2022: 11 · 2021: 17 · 2020: 21 · 2019: 11 · 2018: 19 · 2017: 21 · 2016: 19 · 2015: 10 · 2014: 24 · 2013: 18 · 2012: 15
FWCI
15.75
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
rosiglitazone, metformin, glibenclamide, type 2 diabetes, beta-cell function, insulin sensitivity, oral glucose tolerance test, ADOPT trial, thiazolidinediones, sulfonylureas
MeSH terms
Rosiglitazone, Aged, Diabetes Mellitus, Type 2, Female, Glyburide, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Thiazolidinediones, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT. https://app.cochat.ai/papers/10.2337/db10-1392
The paper
Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., & and the ADOPT Study Group. (2011). Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT. Diabetes. https://doi.org/10.2337/db10-1392

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.